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OBJECTIVE—Evidence favors apolipoprotein B (apoB) over
LDL cholesterol as a predictor of cardiovascular events, but data
are lacking on coronary artery calciﬁcation (CAC), especially in
type 2 diabetes, where LDL cholesterol may underestimate
atherosclerotic burden. We investigated the hypothesis that apoB
is a superior marker of CAC relative to LDL cholesterol.
RESEARCH DESIGN AND METHODS—We performed cross-
sectional analyses of white subjects in two community-based
studies: the Penn Diabetes Heart Study (N  611 type 2 diabetic
subjects, 71.4% men) and the Study of Inherited Risk of Coronary
Atherosclerosis (N  803 nondiabetic subjects, 52.8% men) using
multivariate analysis of apoB and LDL cholesterol stratiﬁed by
diabetes status.
RESULTS—In type 2 diabetes, apoB was associated with CAC
after adjusting for age, sex, and medications [Tobit regression
ratio of increased CAC for 1-SD increase in apoB; 1.36 (95% CI
1.06–1.75), P  0.016] whereas LDL cholesterol was not [1.09
(0.85–1.41)]. In nondiabetic subjects, both were associated with
CAC [apoB 1.65 (1.38–1.96), P  0.001; LDL cholesterol 1.56
(1.30–1.86), P  0.001]. In combined analysis of diabetic and
nondiabetic subjects, apoB provided value in predicting CAC
scores beyond LDL cholesterol, total cholesterol, the total cho-
lesterol/HDL cholesterol and triglyceride/HDL cholesterol ratios,
and marginally beyond non-HDL cholesterol.
CONCLUSIONS—Plasma apoB, but not LDL cholesterol, levels
were associated with CAC scores in type 2 diabetic whites. ApoB
levels may be particularly useful in assessing atherosclerotic
burden and cardiovascular risk in type 2 diabetes. Diabetes 58:
1887–1892, 2009
A
polipoprotein B (apoB) may be more useful
clinically than LDL cholesterol in coronary
heart disease (CHD) because it captures
greater information about atherogenic particles
and is not inﬂuenced by heterogeneity of particle choles-
terol content (1). Measurement of LDL cholesterol is
relatively insensitive to the accumulation of small, dense
LDL particles, which are believed to be highly atherogenic
(1). This is reﬂected in the preponderance of evidence
from prospective epidemiologic studies and statin trials
favoring apoB over LDL cholesterol as a predictor of
cardiovascular risk as well as residual risk on statin
therapy (2–10).
Heterogeneity of LDL particle cholesterol content is
increased in type 2 diabetes because insulin resistance
drives VLDL cholesterol production, leading to depletion
of LDL cholesterol via the action of cholesterol ester
transfer protein (CETP) (11). CETP exchanges triglycer-
ides for cholesterol on LDL particles, which are remodeled
by lipases to produce cholesterol-poor, small, dense LDL
particles (11,12). Because there is one apoB per LDL
particle, regardless of density, apoB detects the presence
of these atherogenic particles, in contrast to LDL choles-
terol, and thus may be better suited to guide lipid-lowering
therapy, particularly in insulin resistance and type 2
diabetes.
Data are lacking on the relationship of apoB to coronary
artery calciﬁcation (CAC), a quantitative measure of sub-
clinical atherosclerosis and predictor of CHD in diabetes
(13) as well as in the general population (14,15). There-
fore, we examined the relative association of plasma apoB
and LDL cholesterol with CAC in two cross-sectional
studies of individuals without known CHD, one recruited
based on type 2 diabetes and the other based on family
history of CHD. We hypothesized that apoB levels would
be stronger predictors of CAC than LDL cholesterol levels,
particularly in type 2 diabetic subjects. We also hypothe-
sized that apoB might add incremental value to traditional
cholesterol-based CHD risk parameters.
RESEARCH DESIGN AND METHODS
Study participants. Details of the Penn Diabetes Heart Study (PDHS) (16,17)
and the Study of Inherited Risk of Coronary Atherosclerosis (SIRCA) (18–20)
have been reported previously. In brief, both are contemporary, single-center,
cross-sectional community-based studies of subjects without clinical evidence
of CHD (deﬁned as myocardial infarction, coronary revascularization, angio-
graphic disease, or positive stress test) recruited at the University of Penn-
sylvania that used the same clinical research center, research staff, electron
beam computed tomography scanner, and lipid laboratory. SIRCA subjects
were recruited in 1995–2005 based on a family history of premature CHD.
PDHS subjects were recruited in 2001–2007 based on type 2 diabetes.
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DIABETES, VOL. 58, AUGUST 2009 1887Exclusion criteria included clinical CHD, elevated creatinine, and, in SIRCA,
the presence of diabetes. This report focuses on unrelated, white subjects
(diabetic participants n  611, nondiabetic participants n  803).
Evaluated parameters. Participants were evaluated at the General Clinical
Research Center at the University of Pennsylvania Medical Center after a 12-h
overnight fast. ApoB and plasma lipids were measured in Penn’s Center for
Disease Control–certiﬁed lipid laboratory. Standard lipid panels and apoB
were measured enzymatically (Cobas Fara II; Roche Diagnostic Systems,
Somervile, NJ) in lipoprotein fractions after ultracentrifugation (-quantiﬁca-
tion technique) in PDHS (21) and in whole serum in SIRCA in a Penn’s Center
for Disease Control–certiﬁed lipid laboratory (21). Analyses use LDL choles-
terol calculated by the Friedewald formula; direct LDL cholesterol measure-
ment was available for diabetic subjects and produced essentially identical
results (data not shown). For apoB and C-peptide response (high sensitivity),
immunoturbidimetric assays were used (16,19). Laboratory test results were
generated by personnel blinded to the clinical characteristics and CAC scores
of research subjects. Clinical parameters, including blood pressure and waist
circumference, were assessed as previously reported (16,18). Framingham
risk scores, using calculated LDL cholesterol (similar results using total
cholesterol), were determined as described by Wilson et al. (22). Subjects
were classiﬁed as having the metabolic syndrome using the revised National
Cholesterol Education Program deﬁnition (glucose cut point 100 mg/dl) (23).
Global CAC scores were quantiﬁed as described (18) according to the method
of Agatston et al. (24) by electron beam tomography.
Statistical analysis. Data are reported as median (interquartile range [IQR])
or mean  SD for continuous variables and as proportions for categorical
variables. The crude association of apoB and LDL cholesterol with lipid,
metabolic, and inﬂammatory parameters was examined by Spearman corre-
lation. Multivariable analysis of CAC scores was performed using Tobit
conditional regression of natural log (CAC1). Tobit conditional regression is
particularly suited to the unusual distribution of CAC data (many zero scores
but also a marked right skew) (18,25). It combines two regression approaches:
ﬁrst, a logistic regression of the presence of CAC (any CAC present versus
CAC zero score) and second, a linear regression (of log-transformed CAC)
when CAC is present. This provides a single estimate for the relationship of
risk factors with CAC data. We present Tobit ratios for CAC score increment
for a 1-SD increase in a lipid parameter, which allows a similarly scaled
comparison of different lipid parameters. A Tobit ratio of 1.30 means that
there is a 30% increase in the CAC score for every SD increase in a lipid
parameter. We also performed secondary logistic regression analysis of the
presence of any CAC.
Our modeling is based on the assumption that current lipoprotein mea-
sures reﬂect prior levels and exposures that contributed to atherosclerosis
over time. The association of apoB, LDL cholesterol, and non-HDL cholesterol
levels with CAC was assessed in incremental models with increasing numbers
of confounding risk factors: Model 1 was adjusted for age, sex, and medica-
tions; model 2 was additionally adjusted for atherosclerotic risk factors
including hypertension, tobacco use, alcohol use, exercise, family history of
premature CHD, C-reactive protein, and metabolic syndrome; whereas for
apoB, model 3 was further adjusted for total cholesterol. Interaction of apoB
and LDL cholesterol with type 2 diabetes was tested by likelihood ratio
testing, and stratiﬁed results are presented when appropriate. Finally, we
applied likelihood ratio testing in nested models to assess the incremental
value of apoB over cholesterol parameters and clinical risk assessments
(Framingham risk score, metabolic syndrome), and vice versa, in predicting
CAC scores. Statistical analyses were performed using Stata 10.0 software
(Stata, College Station, TX).
RESULTS
Characteristics of study samples. Table 1 summarizes
study sample characteristics stratiﬁed by type 2 diabetes
status. Diabetic subjects were older, predominantly male,
more obese, and had lower total and LDL cholesterol as
well as apoB levels (P  0.001 for all), likely reﬂecting
greater use of statin therapy. Fifteen percent of those with
diabetes were on insulin, and median A1C was 6.8%. As
expected, National Cholesterol Education Panel–deﬁned
metabolic syndrome was present in over 75% of type 2
diabetic and 25% of nondiabetic patients. The correlation
of apoB with LDL cholesterol was similar in diabetic (r
2 
0.67) and nondiabetic (r
2  0.64) subjects. Spearman
correlations revealed associations of apoB and LDL cho-
lesterol with other CHD risk parameters that were broadly
similar across diabetes status (Table 2).
Plasma levels of apoB, but not of LDL cholesterol, are
associated with CAC in diabetic participants. In type
2 diabetic whites (Table 3, left columns), apoB [Tobit ratio
for 1-SD increase, 1.36 (95% CI 1.06–1.75), P  0.016], but
TABLE 1
Characteristics of the study sample
Type 2 diabetic
subjects
Nondiabetic
subjects
n 611 803
Age (years) 60 (54–68) 48 (42–54)
Male (%) 71.4 52.8
Total cholesterol (mg/dl) 174 (152–198) 205 (177–228)
HDL cholesterol (mg/dl) 45 (37–53) 48 (39–59)
Triglycerides (mg/dl) 134 (92–197) 117 (87–159)
LDL cholesterol (mg/dl) 97 (79–119) 126 (103–148)
ApoB (mg/dl) 82 (71–94) 98 (84–114)
Medications
Statin (%) 57.4 13.9
Niacin (%) 5.6 3.0
Fibrate (%) 10.0 1.1
Insulin (%) 14.9 N/A
Metformin (%) 63.8 N/A
Thiazolidinediones (%) 27.3 N/A
Sulfonylureas (%) 40.3 N/A
Ten-year Framingham
risk (%) 13 (8–20) 5 (3–8)
Current smoking (%) 8.4 11.3
Alcohol use (%) 58.4 67.8
Blood pressure (mmHg)
Systolic 131 (122–140) 126 (117–136)
Diastolic 75 (71–81) 77 (72–84)
BMI (kg/m
2) 32 (28–36) 27 (24–30)
Waist circumference (cm) 107 (98–117) 89 (81–99)
Metabolic syndrome (%) 76.6 25.8
C-reactive protein (mg/dl) 1.6 (0.8–3.4) 1.2 (0.5–2.6)
CAC
Mean score (SD) 424  795 87  266
Median (IQR) 89 (1–456) 3 (0–45)
0 (%) 75.3 68.9
100 (%) 49.1 16.4
400 (%) 26.8 5.4
Data are median (IQR) or percent, unless otherwise noted.
TABLE 2
Spearman correlations of lipid, metabolic, and inﬂammatory
variables with plasma apoB and LDL cholesterol
Type 2 diabetic
subjects (n  611)
Nondiabetic
subjects (n  803)
ApoB
LDL
cholesterol ApoB
LDL
cholesterol
Total cholesterol 0.78‡ 0.90‡ 0.77‡ 0.90‡
HDL cholesterol 0.21‡ 0.02 0.21‡ 0.03
Triglycerides 0.47‡ 0.15‡ 0.51‡ 0.18†
Glucose 0.20‡ 0.07 0.12‡ 0.02
Waist circumference 0.08* 0.004 0.25‡ 0.13‡
BMI 0.07 0.05 0.23‡ 0.13‡
Framingham risk 0.43‡ 0.41‡ 0.50‡ 0.38‡
Blood pressure
Systolic 0.05 0.01 0.20‡ 0.14‡
Diastolic 0.14‡ 0.05 0.20‡ 0.12‡
C-reactive protein 0.17‡ 0.05 0.25‡ 0.12‡
*P  0.05, †P  0.01, ‡P  0.001.
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CAC after adjusting for age, sex, and lipid-lowering and
diabetes medications. In nondiabetic patients (Table 3,
right columns), both apoB [1.65 (1.38–1.96), P  0.001]
and LDL cholesterol [1.56 (1.30–1.86), P  0.001] were
associated with CAC in this simple model. After further
adjusting for multiple cardiovascular risk factors, this
pattern of CAC association persisted (Table 3). Even after
adjusting for total cholesterol, apoB continued to have a
strong association with CAC in diabetic subjects [1.83
(1.17–2.85)], whereas in nondiabetic subjects, this was
attenuated [1.22 (0.90–1.65)]. In combined analysis of
diabetic and nondiabetic subjects, interaction analysis
suggested a consistent CAC association for apoB (diabetes
interaction P  0.25), but a difference by diabetes status in
the relationship of LDL cholesterol with CAC (interaction
P  0.02). Results of logistic regression of the presence of
CAC were similar to that for Tobit modeling (see Appendix
Table1,availableonlineathttp://diabetes.diabetesjournals.
org/cgi/content/full/db08-1794/DC1). To explore the effect
of greater statin use in the diabetic versus nondiabetic
samples, we performed a secondary analysis excluding
statin users. These analyses yielded analogous ﬁndings to
the full sample for the pattern of apoB, LDL cholesterol,
and other lipid relationships with CAC (Appendix Table 2
in the online appendix).
In diabetic participants, plasma levels of non-HDL cho-
lesterol had stronger CAC association than LDL choles-
terol but less than that for apoB. In contrast, non-HDL
cholesterol had almost identical CAC association as apoB
in nondiabetic whites (Table 3; Appendix Tables 1 and 2 in
the online appendix).
Incremental value of apoB levels over cholesterol-
based risk parameters. We combined data across dia-
betic and nondiabetic subjects and assessed the
incremental value of apoB over cholesterol parameters
(Table 4, top rows). ApoB added value in predicting CAC
scores when added to LDL cholesterol and total choles-
terol. In fact, it also added value to the total cholesterol/
HDL cholesterol and triglyceride/HDL cholesterol ratios
and marginally to non-HDL cholesterol. In contrast, adding
LDL cholesterol, total cholesterol, and non-HDL choles-
terol to apoB failed to provide additional value (Table 4,
bottom rows). As expected, because they contain HDL
data, the total cholesterol/HDL cholesterol and triglycer-
ide/HDL cholesterol ratios added value to apoB in predict-
ing CAC score. Notably, apoB provided incremental value
in predicting CAC beyond Framingham risk scores, sug-
gesting utility beyond current approaches in clinical prac-
tice. In secondary analyses, stratiﬁed by diabetes status,
apoB also added value to LDL cholesterol in those with
and without type 2 diabetes (Appendix Table 3). ApoB’s
additive value to non-HDL cholesterol and HDL choles-
terol containing parameters was attenuated, however,
likely because of reduced power in the smaller strata.
TABLE 3
Association of plasma levels of apoB and cholesterol parameters with CAC
Variables adjusted for
Type 2 diabetic subjects
(n  611)
Nondiabetic subjects
(n  803)
*Tobit ratio (95% CI) *Tobit ratio (95% CI)
ApoB
Age, sex, medications *1.36 (1.06–1.75) 1.65 (1.38–1.96)
Age, sex, medications, risk factors 1.37 (1.05–1.79) 1.50 (1.25–1.80)
LDL cholesterol
Age, sex, medications 1.09 (0.85–1.41) 1.56 (1.30–1.86)
Age, sex, medications, risk factors 1.13 (0.87–1.47) 1.51 (1.27–1.81)
Non-HDL cholesterol
Age, sex, medications 1.30 (1.01–1.68) 1.68 (1.41–2.00)
Age, sex, medications, risk factors 1.28 (0.99–1.67) 1.54 (1.29–1.85)
Results of Tobit conditional regression are presented as the ratio of increase in CAC score for 1-SD increase in apoB (17.84 mg/dl in diabetic
subjects; 22.83 mg/dl in nondiabetic subjects), LDL cholesterol (31.63 mg/dl in diabetic subjects; 35.08 mg/dl in nondiabetic subjects), or
non-HDL cholesterol (36.91 mg/dl in diabetic subjects; 38.79 mg/dl in nondiabetic subjects). *Tobit ratio of 1.36 means that for every 17.84
mg/dl (1-SD) increase in apoB, there is a 36% increase in the CAC score. Medications included statins, niacin, ﬁbrates, insulin, metformin,
thiazolidinediones, sulfonylureas, and hormone replacement therapy. Risk factors included hypertension, tobacco use, alcohol use, exercise,
family history of premature cardiovascular disease, C-reactive protein, and metabolic syndrome.
TABLE 4
Relative value of apoB and cholesterol parameters in predicting
CAC scores in diabetic and nondiabetic subjects
All subjects
(n  1,414)
	
2 P value
ApoB added to
LDL cholesterol 15.26 0.001
Total cholesterol 16.65 0.001
Non-HDL cholesterol 3.2 0.07
HDL cholesterol 24.37 0.001
Triglyceride/HDL cholesterol ratio 17.31 0.001
Total cholesterol/HDL cholesterol
ratio 4.32 0.04
Framingham risk score and
metabolic syndrome 16.09 0.001
Cholesterol parameter(s) added to
apoB
LDL cholesterol 0.29 0.59
Total cholesterol 0.54 0.46
Non-HDL cholesterol 1.54 0.21
HDL cholesterol 9.25 0.002
Triglyceride/HDL cholesterol ratio 12.39 0.001
Total cholesterol/HDL cholesterol
ratio 10.79 0.001
Likelihood ratio testing was applied in nested Tobit models to assess
the incremental value of apoB over cholesterol parameters, and vice
versa, in predicting CAC scores. All models included age, sex,
medications, and diabetes status.
S.S. MARTIN AND ASSOCIATES
DIABETES, VOL. 58, AUGUST 2009 1889DISCUSSION
We report that apoB, but not LDL cholesterol, was asso-
ciated with CAC scores in type 2 diabetic whites. This was
true despite relatively high correlations of these two lipid
parameters in diabetic subjects. In contrast, both apoB
and LDL cholesterol were equally associated with CAC in
nondiabetic patients. Although non-HDL cholesterol was
superior to LDL cholesterol, we found that apoB added
incremental value to total cholesterol and LDL cholesterol
and even tended to add to non-HDL cholesterol in CAC
prediction, whereas the reverse was not true. Overall,
these ﬁndings support the concept that apoB levels may be
stronger predictors of atherosclerotic burden than LDL
cholesterol and other cholesterol parameters in type 2
diabetes.
Robust evidence from large primary and secondary
prevention clinical trials established the standard practice
of LDL cholesterol lowering for CHD prevention (26).
Contemporary data have reﬁned our interventions toward
more aggressive therapeutic targets (27), yet the majority
of CHD events are not prevented. One potential means of
improving outcomes is through more precise estimation of
atherogenic lipoprotein parameters, beyond cholesterol
content, that more fully capture CHD risk.
ApoB, a measure of LDL particle number (LDL-P), as
well as total atherogenic particle number, may represent
such a parameter. In most (2–10), but not all (28–30), prior
reports, including several large, prospective epidemiolog-
ical studies and clinical trials, apoB surpassed LDL cho-
lesterol and other cholesterol parameters, as a predictor of
new and recurrent CHD events and marker of residual risk
on therapy. Concordantly, apoB is the top performer in our
study, relative to LDL cholesterol, and even to non-HDL
cholesterol, which, unlike apoB, loses signiﬁcance in the
diabetic group after adjustment for age, sex, medications,
and risk factors (Table 3, P  0.07). Although our sample
was relatively small, large clinical studies also favor apoB
over non-HDL cholesterol. Notably, when Pischon et al.
(4) compared apoB head to head against LDL cholesterol
and non-HDL cholesterol in a nested case-control study of
18,225 asymptomatic men in the Health Professionals
Follow-up Study, apoB emerged the leading predictor of
incident CHD. Although, non-HDL cholesterol was equal to
apoB in CHD prediction in type 2 diabetes (31) and healthy
women (28), the majority of clinical evidence, contempo-
rary expert reviews, and consensus statements (1,5,32,33)
as well measurement characteristics (5) favor apoB over
non-HDL cholesterol. However, debate continues as to the
optimal choice and application in clinic (33).
The INTERHEART study (34) extended the generaliz-
ability of apoB’s utility in CHD risk prediction across a
30,000-person, ethnically diverse population, spanning ev-
ery major continent. INTERHEART, along with other
reports, support value in the apoB/apoA1 ratio, though
data are mixed on whether apoA1 is superior, or even
equal, to HDL cholesterol, as discussed in a recent review
by Sniderman and Marcovina (32). Consistent with these
ﬁndings, we found that plasma apoB, but not LDL choles-
terol levels, were independently associated with CAC
scores in type 2 diabetes. In fact, other than HDL choles-
terol parameters, no cholesterol data added value to apoB.
HDL cholesterol captures separate, anti-atherogenic ef-
fects (35), but may also provide information because of its
inverse association with insulin resistance and positive
correlation with LDL particle size (36). Our ﬁndings fur-
ther support apoB’s superiority over LDL cholesterol, as
well as other cholesterol-based measures, and break new
ground in relating apoB to subclinical coronary atheroscle-
rosis, particularly in type 2 diabetes.
Among the laboratory methods that currently exist for
determination of LDL-P, apoB is the most mature and
cost-effective. It is broadly equivalent to LDL-P because
each LDL particle, independent of density, contains ex-
actly one apoB and the vast majority (90%) of apoB is
carried on LDL particles (32). In this way, apoB is not
affected by heterogeneity of particle cholesterol content.
Such heterogeneity is greater in type 2 diabetes because
insulin resistance drives VLDL cholesterol production that
depletes LDL particles of their cholesterol content via
CETP, producing cholesterol-poor small, dense LDL parti-
cles (11). Remarkably, the remainder of apoB is carried on
chylomicrons, VLDL cholesterol, intermediate-density li-
poprotein, and lipoprotein(a) and thus also captures infor-
mation on residual non-LDL atherogenic particles. ApoB
measurement is standardized (37) and automated, yielding
cost, time, and precision advantages over other modalities.
It is available in most large commercial laboratories and
does not require a fasting state. Thus, apoB has several
measurement-related advantages as a marker of lipid risk.
Nuclear magnetic resonance (NMR) is an alternative
means of measuring LDL-P; however, its clinical utility is
currently limited because it is expensive and not widely
available across laboratories. Nevertheless, reports on its
predictive power in CHD are revealing. NMR-measured
LDL-P improved cardiovascular risk estimation over LDL
cholesterol in several cross-sectional (38) and prospective
studies (39–43). Cross-sectional studies of healthy individ-
uals showed that LDL-P was associated with CAC in
postmenopausal women (44) and carotid intima-media
thickness in the 5,538-person Multi-Ethnic Study of Ath-
erosclerosis study (38). Prospectively, LDL-P predicted
incident CHD in healthy (39,41,43) and at-risk (42) popu-
lations, as well as progression of CHD (40). In a nested
case-control analysis of 2,888 subjects from the European
Prospective Investigation Into Cancer and Nutrition-Nor-
folk, LDL-P outperformed LDL cholesterol as a predictor
of future coronary artery disease beyond the Framingham
risk score, but not triglycerides and HDL cholesterol (43).
Although NMR has the capacity to estimate LDL particle
size as well as particle number (43), there is limited
evidence that NMR-estimated lipid data add value beyond
the more simple measurement of apoB (33,41,42).
Patients with type 2 diabetes tend to have increased
circulating LDL particles but normal concentrations of
LDL cholesterol because their particles have low choles-
terol content (45). Despite elevated triglycerides and low
HDL cholesterol, this normal LDL cholesterol has led to
underappreciation of the risk associated with dyslipidemia
in diabetes. Indeed, in type 2 diabetic subjects, apoB and
non-HDL cholesterol were favored over LDL cholesterol as
predictors of CHD risk in the Health Professional’s Fol-
low-Up Study (31). Our data also shows apoB and non-
HDL cholesterol capture information beyond LDL
cholesterol in type 2 diabetes. We go further, in agreement
with the recent Casale Monferrato Study (46) and Collab-
orative Atorvastatin Diabetes Study (47), in suggesting
utility of apoB measurement over cholesterol parameters,
including non-HDL cholesterol. Casale Monferrato looked
at 11-year CHD mortality in 1,565 Mediterranean subjects
with type 2 diabetes and found apoB predicted outcome
independent of non-HDL cholesterol. CARDS followed
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points over 3.9 years. ApoB carried a very similar hazard
ratio to non-HDL cholesterol [adjusted hazard ratio (95%
CI) for 1-SD increment: 1.20 (1.04–1.38) vs. 1.17 (1.02–
1.34), respectively], but apoB was the stronger predictor
(	
2 6.61; P  0.01 vs. 	
2 4.71; P  0.03). In receiver
operating characteristic analysis, the area under the curve
for apoB versus non-HDL cholesterol was signiﬁcantly
greater (P  0.01). Overall, our data support others’ in
suggesting that apoB is likely to be an enhanced measure
of subclinical coronary atherosclerosis and lipid-associ-
ated CHD risk beyond traditional lipid risk factors in type
2 diabetes.
Our study has several limitations. Analyses were cross-
sectional; thus, causal and longitudinal relationships were
not addressed. ApoB’s stronger association with CAC
might reﬂect less variability in its measurement, especially
over time, relative to LDL cholesterol. However, we can-
not differentiate this possibility from a true stronger apoB
association with CAC in our cross-sectional study. We also
did not examine clinical outcomes, although our data are
consistent with large clinical outcomes studies. Moreover,
given lipid (48) and CAC (49) variability by race, our
ﬁndings cannot be generalized beyond whites. In addition,
CAC is an estimate (14,50) and not a direct measure of
coronary atherosclerosis; thus, it may fail to detect some
coronary atherosclerotic plaques. Despite this limitation,
CAC scores are clinically relevant because they are strong,
independent predictors of CHD (14,15), including in dia-
betic subjects (13). In our study, there was also extensive
and differential statin use between diabetic and nondia-
betic participants. Although this could confound the re-
sults, it represents real-world practice. In fact, we found
that apoB predicted CAC even after controlling for differ-
ences in statin use and in subgroup analysis of nonstatin
users.
Ours is the ﬁrst study to show that plasma apoB, but not
LDL cholesterol, levels are associated with CAC beyond
traditional risk factors in type 2 diabetic whites. LDL
cholesterol and cholesterol-related parameters did not add
value to apoB. These results for subclinical coronary
atherosclerosis agree with clinical outcomes data support-
ing apoB as a predictor of cardiovascular events. Our
ﬁndings are broadly consistent with a recent joint consen-
sus statement from the American Diabetes Association
and American College of Cardiology that recommends
incorporating apoB in managing patients with cardiometa-
bolic risk (33). We advance previous apoB literature by
addressing its relationship to subclinical coronary athero-
sclerosis in type 2 diabetic patients free of clinical CHD
and we provide data that apoB may warrant greater use in
risk assessment beyond LDL cholesterol in these asymp-
tomatic individuals at higher cardiometabolic risk.
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